REGULATED INFORMATION

       Nyxoah Reports First Quarter 2024 Financial and Operating Results
         Announced DREAM U.S. pivotal study achieved primary endpoints
               On track for FDA approval as early as end of 2024

Mont-Saint-Guibert, Belgium - May 14, 2024 10:05pm CET / 4:05pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the first quarter of 2024.
Recent Financial and Operating Highlights
* Reported the DREAM U.S. pivotal study achieved co-primary endpoints on an
intent-to-treat (ITT) basis and demonstrated strong AHI reductions in supine

    and non-supine sleep positions.
  * The DREAM study achieved a median AHI reduction of 70.8%, a 12-month AHI
    responder rate, per the Sher criteria, of 63.5% (p=0.002) on an ITT basis

and a 12-month ODI responder rate of 71.3% (pÂ